The move to Nasdaq: Successful Public Offering of Evotec SE
Public offering at Nasdaq: Evotec SE
Evotec is an industry-leading and internationally active drug discovery and development partner for the pharmaceutical and biotechnology industries. Evotec’s shares were previously traded in the Prime Standard of the Frankfurt Stock Exchange and included in the MDAX and TecDAX indices.
The U.S. public offering (dual listing) took place by way of a capital increase from authorized capital in the amount of 10,000,000 new shares, which were admitted to trading on Nasdaq in the form of 20,000,000 so-called American Depositary Shares (ADS). The underwriters also partially exercised the option granted to them to place up to 3,000,000 additional ADS (greenshoe).
The U.S. public offering reportedly raised total proceeds of approximately €500 million for Evotec, which will be used, among other things, to expand its biologics manufacturing capacity. In particular, the Nasdaq listing will enable Evotec to further increase its visibility in the world’s biggest pharmaceutical market.
This deal marks another successful US public offering for the FINLEX-Team, which has previously advised other top tier clients from the biotech and pharma industry.
The team advising Evotec includes Nathalie Wache (Financial Lines Expert), Florian Eckstein (Practice Lead IPOs and Capital Markets) and Sebastian Klapper (Founder & Managing Director) along with its US co-broker team of Woodruff Sawyer from San Francisco.
The following images are released for reprinting subject to editorial, non-commercial use.
Nathalie Wache | (Press photo)
Photo credits: Finlex GmbH
Florian Eckstein | (Press photo)
Photo credits: Finlex GmbH
Sebastian Klapper | (Press photo)
Photo credits: Finlex GmbH
Download our Press release.
About Finlex GmbH
Finlex – the online insurance platform for commercial and industrial clients – aims to be the leading digital marketplace for financial lines business segments throughout Europe. This includes D&O, cyber, legal expenses, fidelity, pecuniary loss liability and capital market transaction insurance. Finlex focuses on digitization, along with outstanding technical expertise.
The InsurTech Radar 2021, recently published by Oliver Wyman, considers Finlex one of the few ‘scale-ups’ with enormous potential. Scale-ups are start-ups that show rapid growth already after the initial phase.
Finlex is headquartered in Frankfurt am Main, with offices in Berlin, Barcelona, Düsseldorf and Vienna.
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products.
Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.
Presse contact
Finlex GmbH
Denise Jetzki | Marketing Expert
E-Mail: marketing@finlex.io
Telefon: +49 69 8700 142-0
finlex.io
Similar Posts

Finlex bietet neue digitale Strafrechtsschutz-Versicherung für Unternehmen an
In Zeiten zunehmender strafrechtlicher Ermittlungen gegen Unternehmensleiter und Manager erweitert das InsurTech Finlex seine Produktpalette und bietet ab sofort eine…

Finlex expands management team with Andrea Kotter as Vice President Cyber
On November 1st, the renowned Cyber expert, Andrea Kotter, will join Finlex. She comes from Munich Re, one of the…

Gothaer offers Professional Indemnity Insurance for insolvency administrators on Finlex platform
Gothaer Allgemeine Versicherung AG and Finlex GmbH ramp up their collaboration. From mid-August, as part of an additional special scheme,…

Corvus joins Finlex’ Cyber Fast Lane
Finlex GmbH, the leading online platform in the field of cyber insurance, has added Corvus as another insurer to the…

Finlex launches in France – aiming to become Europe's Central Financial Lines Marketplace
Present in Austria for one year now, the scale-up which underwrote nearly 100 million Euro in premiums in 2022 and…

Finlex provides new digital concept for criminal legal protection for companies
[vc_column width="1/1"]In times of increasing criminal investigations against business leaders and managers, InsurTech company, Finlex, is expanding its product range…

UNIQA and Finlex join forces in financial lines sector
[vc_column width="1/1"]More than 140 platform users already benefit from Finlex’s digital marketplace, which went live in Austria in May 2022.…

Cyber insurance: Finlex simplifies placement process for SMEs
Finlex has established the "Cyber Fast Lane", a new and simple process for the Cyber insurability of small to medium-sized…

The Finlex France team continues to grow with the appointment of Sophie Delcourt and Frédéric Rousseau.
Finlex is pleased to announce that the French team continues to grow with the arrival of Sophie Delcourt as Head…

Finlex continues to grow its Austrian team
Finlex, one of the most successful German InsurTechs, is also showing strong growth in Austria and is strengthening its Vienna…